ESR1 and breast cancer: Although tamoxifen is the most efficient in current approaches for estrogen receptor α positive (ERα+) BC, which make up the maximal proportion of BC patients, development of resistance to tamoxifen in connection with metastatic recurrence occurs in most patients during the treatment.